Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulinotropic meglitinide analogues.

A Dornhorst1

  • 1Department of Metabolic Medicine, Faculty of Medicine, Imperial College, Hammersmith Hospital Campus, Du Cane Road, W12 0NN, London, UK. a.dornhorst@ic.ac.uk

Lancet (London, England)
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increasing the proportion of plasma MUFA, as a result of dietary intervention, is associated with a modest improvement in insulin sensitivity.

Journal of nutritional science·2020
Same author

Pregnancy in Diabetes: challenges and opportunities for improving pregnancy outcomes.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Plasma free fatty acids do not provide the link between obesity and insulin resistance or β-cell dysfunction: results of the Reading, Imperial, Surrey, Cambridge, Kings (RISCK) study.

Diabetic medicine : a journal of the British Diabetic Association·2014
Same author

Diabetic ketoacidosis: not always due to type 1 diabetes.

BMJ (Clinical research ed.)·2013
Same author

In vitro fertilization treatment influences glucose tolerance in multiple pregnancy.

Diabetic medicine : a journal of the British Diabetic Association·2012
Same author

Development and evaluation of a standardized registry for diabetes in pregnancy using data from the Northern, North West and East Anglia regional audits.

Diabetic medicine : a journal of the British Diabetic Association·2011
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Loss of early insulin secretion is key in type 2 diabetes. New meglitinide drugs can restore this, potentially delaying the need for insulin therapy.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Early-phase insulin secretion is crucial for managing postprandial metabolism.
  • Type 2 diabetes is characterized by the loss of this early insulin release.
  • Conventional oral hypoglycemic agents inadequately control postprandial glucose levels.

Purpose of the Study:

  • To explore the rationale for developing agents targeting early-phase insulin release.
  • To introduce meglitinide analogues as a novel therapeutic class for type 2 diabetes.
  • To discuss the potential of these agents in combination therapies.

Main Methods:

  • Review of existing literature on type 2 diabetes pathophysiology and treatment.
  • Analysis of the mechanism of action of meglitinide analogues.

Related Experiment Videos

  • Evaluation of potential combination therapies with metformin and thiazolidinediones.

    • Main Results:

    • Meglitinide analogues (repaglinide, nateglinide, mitiglinide) can restore early-phase insulin release.
    • These agents are suitable for combination with metformin.
    • Potential efficacy in combination with thiazolidinediones, which address insulin resistance.

    Conclusions:

    • Newer oral agents, specifically meglitinides, offer a targeted approach to restoring early insulin secretion.
    • Combination therapies involving meglitinides may improve glycemic control and potentially extend beta-cell function.
    • The goal is to delay the eventual need for exogenous insulin in type 2 diabetes management.